Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)
Study sponsor: Fulcrum Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-11-19Actual
Enrollment · participants260Actual
Source updated2025-11-10Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.